Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$56.38 USD
+0.39 (0.70%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $56.40 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 81 - 100 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Recap - Programs On Track; Valuation at Discount
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; VK2809 and VK0214 Continue to Move Forward Despite COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Durable Effects of VK2809 and Our Investment Case; Target Upped to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; VK0214 Is Approaching the Clinic While VK2809 Continues Its VOYAGE
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Trial Operations and Pipeline Development Continue Despite COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Recap - VOYAGE Trial Progressing (Modest COVID-19 Delays)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Recap - Target VK2809 Enrollment Completion by End of 2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; VOYAGE Ramping up; Target Adjusted to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VOYAGE Begins in Earnest to Our Projected Success for VK2809
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Recap - VK2809 Trial Expected to Start This Quarter
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S